Zachary Scott Morris

This study shows that optimized spatially heterogeneous radiopharmaceutical therapy enhances immune checkpoint blockade response in poorly immunogenic tumors by promoting T cell activation and infiltration.

This study shows that low-dose radiopharmaceutical therapy enhances the effectiveness of B7-H3 CAR T cells in treating metastatic neuroblastoma in mice.

This study shows that heterogeneous radiation dose in tumors enhances anti-tumor immunity and correlates with better clinical outcomes in prostate cancer patients.

This study compares the immune effects of alpha- and beta-particle emitting radiopharmaceuticals combined with immune checkpoint inhibitors in murine tumor models, finding distinct mechanisms of action based on radiation type.

The paper shows CD4 T regulatory cells can kill tumor cells through trogocytosis after immunocytokine treatment in a melanoma model.

The paper identifies SUZ12's nucleic acid-binding domain as critical for regulating PRC2 activity in H3 K27M gliomas, showing how it constrains enzymatic function and maintains targeted gene silencing.

This paper shows that low-dose radiopharmaceutical therapy enhances GD2 TRAC-CAR T cell efficacy in neuroblastoma by improving tumor regression and immune response.

This study examines how different radionuclides affect the type I interferon response in tumor models and shows that 225Ac enhances immunotherapy response via STING-dependent mechanisms.

The paper introduces PROD-ATAC, a method to study chromatin effects of protein-coding variants, revealing common dysregulation mechanisms across oncofusions and cancers.